• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Sumitomo Dainippon Pharma and BehaVR announce landmark deal for multiple virtual reality digital therapeutics

Development and commercialization plans include prescription digital therapeutics to treat social anxiety, generalized anxiety disorder, and major depressive disorder - with potential to impact millions worldwide.

BehaVR.com, freedom from stress, anxiety and fear.

News provided by

BehaVR

Oct 18, 2021, 08:30 ET

Share this article

Share this article


OSAKA, Japan and NASHVILLE, Tenn., Oct. 18, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) and BehaVR, Inc.,(Head Office: TN, U.S.) announce today that the companies have signed definitive agreements to develop and commercialize both prescription digital therapeutics and general wellness products for treatment of Social Anxiety Disorder (SAD), Generalized Anxiety Disorder (GAD), and Major Depressive Disorder (MDD) with the goal of bringing much needed tools to tackle the escalating global anxiety and depression crisis.

Continue Reading

Sumitomo Dainippon Pharma and BehaVR announce landmark deal for multiple virtual reality digital therapeutics.

Tweet this
BehaVR, Step inside a new world...
BehaVR, Step inside a new world...

This collaboration combines BehaVR's design and product development capabilities with Sumitomo Dainippon Pharma's expertise in developing prescription therapeutics for patients with CNS-related disorders. It also leverages key strengths from each company's go-to-market and commercial capabilities. The companies believe the unique neurological power of the virtual reality (VR) medium will transform access to care and power next generation delivery of anxiety and depression treatment for patients. The companies will pursue FDA clearance for three products that aim to alleviate the burden in patients with Social Anxiety, Generalized Anxiety or Major Depressive Disorder. Once FDA-cleared, they may be prescribed alongside other behavioral therapies and have the potential to be used in a variety of settings.

Sumitomo Dainippon Pharma has agreed to fund development of these novel VR therapies and to commercialize them globally upon achievement of each country's regulatory approvals. Sumitomo Dainippon Pharma will pay BehaVR $5 million in upfront payments and up to $18 million in development milestone and R&D support payments, in addition to commercial and operational support fees. An additional up to $140 million in milestone payments are contingent upon commercial success. In addition, BehaVR will receive tiered royalties on global sales of the digital therapeutic products that are delivered into market.

"This continued investment in our collaboration with BehaVR demonstrates Sumitomo Dainippon Pharma's commitment to meet patients' unmet behavioral health needs by developing digital therapies that go beyond pharmacological interventions. There is inadequate access to high quality mental health therapists in every country across the world. Our goal is to deliver high-impact digital VR therapies that are evidence-based to a broad global population of patients that continue to struggle with SAD, GAD, and MDD," said Hiroyuki Baba, Senior Executive Officer, Sumitomo Dainippon Pharma.  "We are excited and proud to be pioneering the use of this fast-moving new medium of Virtual Reality to develop treatments for anxiety and depression related mental illnesses. I could not be more pleased with this extension to our important partnership with BehaVR, who share our vision of the impact that these new products will make."

According to numerous reports by the National Institutes of Health, Center for Disease Control and the World Health Organization, anxiety levels are rising with over 19% of US adults suffering from an anxiety disorder and 5% of adults suffering from depression worldwide. The global COVID-19 pandemic has accelerated the issues. Both depression and anxiety are major contributors to the overall global burden of disease and rise of substance abuse. The treatment gap between the number of people with mental disorders and the number treated represents a major public health challenge. Sumitomo Dainippon Pharma and BehaVR believe that new approaches are needed to address these conditions, including commercializing the 20-year body of research that shows that the application of VR can be used in support of better patient outcomes.

"In my opinion, Sumitomo Dainippon Pharma is one of the most forward thinking and innovative pharmaceutical companies in the world today. We are thrilled to deepen our relationship to jointly increase our impact on health via clinically validated, FDA-cleared Virtual Reality-based digital therapies. Sumitomo Dainippon Pharma's clinical and commercial expertise in this space will advance our joint objective of successfully scaling effective treatment options for anxiety and depression," said Aaron Gani, Founder and CEO of BehaVR.

"Together we are innovating at the vanguard of digital therapeutics and early clinician, patient and consumer responses are extremely favorable. We believe this deep partnership between a global pharmaceutical company Sumitomo Dainippon Pharma and VR digital therapeutics leader is a significant advance for the field of Virtual Reality in healthcare, and for digital therapeutics broadly," said Senator Bill Frist, MD, Founding Partner, BehaVR.

Understanding Virtual Reality Based Prescription Digital Therapeutics
Prescription Digital Therapeutics (PDTs) are clinically validated software-based interventions that prevent, manage, or treat a medical disease or disorder. PDTs are approved by regulators and available by prescription for use alone or alongside other medications or medical devices. BehaVR is creating VR PDTs informed by decades of neuroscience and cognitive research, along with evidence-based protocols that are translated into the medium to treat those with anxiety and depression. The intent of these three products, in this collaboration, is that they will be classified as a Software as a Medical Device (SaMD) and will fall under the FDA regulatory framework that supports innovation and commercialization of digital tools while protecting patient health.

About the Collaboration between Sumitomo Dainippon Pharma and BehaVR 
Sumitomo Dainippon Pharma's wholly-owned US subsidiary, Sunovion Pharmaceuticals Inc. and BehaVR, signed an initial collaboration agreement in June 2020 to co-develop a wellness product for those who suffer from stressful, fearful, and overwhelming feelings in a social setting. This initial collaboration was the foundation for this expanded relationship to develop and commercialize three prescription digital therapeutics for social anxiety, generalized anxiety and major depression upon achievement of regulatory approvals.

About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma defines its corporate mission as "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." By channeling our efforts into the research and development of new drugs, Sumitomo Dainippon Pharma aims to realize its corporate mission and provides innovative and effective pharmaceutical solutions to people in Japan and globally. Sumitomo Dainippon Pharma's goal is to create innovative pharmaceutical products in the focus research areas with high unmet medical needs of Psychiatry & Neurology, Oncology, and Regenerative Medicine / Cell Therapy. In business fields other than pharmaceuticals, too, Sumitomo Dainippon Pharma is working on research and development and commercialization of innovative healthcare solutions under the framework of a frontier business, which goes beyond the traditional boundaries of a pharmaceutical company, with the aim of contributing to "wide-ranging well-being."

Additional information about Sumitomo Dainippon Pharma is available through its corporate website at https://www.ds-pharma.com.

About BehaVR, Inc.
BehaVR is a new kind of digital therapeutics company dedicated to tackling the epidemic of anxiety-related challenges and disorders, to help curb chronic disease at scale, using the neurological power of VR. Partnering with the country's leading academic institutions, research institutes and pharmaceutical companies, we innovate at the intersection of behavioral science, virtual reality, and community design to develop immersive, evidence-based experiences that change peoples' lives. At the core of our products is our stress, anxiety, and fear extinction (S.A.F.E.) protocol. S.A.F.E. builds a powerful foundation of short-term coping skills and long-term resiliency tools — giving people agency over their own health, and generating value, change, and better clinical outcomes for all stakeholders in the healthcare system.

The BehaVR Scientific Advisory Board includes leading researchers and authorities in the fields of behavioral neuroscience and medical virtual reality technology, including Amelia Aldao, PhD., Walter Greenleaf, Ph.D., Hunter Hoffman, Ph.D., Adriaan Louw, PT, Ph.D., and M. Zachary Rosenthal, PhD,  For more information, visit www.behavr.com.

Media Contacts:
Sumitomo Dainippon Pharma Co., Ltd.
Corporate Communications
TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)

BehaVR
Rory Channer
[email protected]
703-989-0014

References

  1. Anjel Vahratian, Stephen J. Blumberg,  Emily P. Terlizzi,, and Jeannine S. Schiller. Symptoms of Anxiety or Depressive Disorder and Use of Mental Health Care Among Adults During the COVID-19 Pandemic, August 2020–February 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 2; 70(13): 490–494.
  2. Evans-Lacko S, Aguilar-Gaxiola S, Al-Hamzawi A, et al. Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys. Psychol Med. 2018;48(9):1560-1571. 
  3. World Health Organization.  Newsroom, Fact Sheets, Depression. 30 January 2020 Available at:  https://www.who.int/news-room/fact-sheets/detail/depression
  4. Maria A. Villarroel, Ph.D., and Emily P. Terlizzi, M.P.H. Symptoms of Depression Among Adults: United States, 2019. NCHS Data Brief No. 379, September 2020
  5. NIH, Anxiety Disorders Fact Sheet; https://www.nimh.nih.gov/health/statistics/any-anxiety-disorder

SOURCE BehaVR

Related Links

http://behavr.com

Modal title

Also from this source

BehaVR and OxfordVR Combine and Raise Series B to Create Largest VR Delivery Platform for Evidence-Based Digital Therapeutics

BehaVR and OxfordVR Combine and Raise Series B to Create Largest VR Delivery Platform for Evidence-Based Digital Therapeutics

Explore

More news releases in similar topics

  • Health Care & Hospitals
  • Biotechnology
  • Medical Pharmaceuticals
  • Mental Health
  • Licensing

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.